Literature DB >> 7764459

Clinical significance of cellular resistance in tumours to cytotoxic chemotherapy and radiotherapy.

M Pomeroy1, M Moriarty.   

Abstract

Cellular resistance is a significant component of tumour treatment failure. More detailed understanding of resistance mechanisms has enabled us to plan circumvention strategies, though these are not yet in routine clinical use. Such resistance is, however, only one of several factors which render cure of advanced malignant disease difficult. It is important for researchers in this field to see not only therapeutic opportunities but also limitations of these approaches. It is hoped that increased cooperation between clinicians and scientists in the field of cellular resistance will yield further improvement in tumour response rates and cure.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7764459     DOI： 10.1007/BF00744675

Source DB:  PubMed          Journal:  Cytotechnology        ISSN： 0920-9069            Impact factor:   2.058


  35 in total

Review 1.  Clinical significance of erbB-2 (HER-2/neu) protein.

Authors:  S Paik
Journal:  Cancer Invest       Date:  1992       Impact factor: 2.176

2.  ARCON: accelerated radiotherapy with carbogen and nicotinamide.

Authors:  A Rojas
Journal:  BJR Suppl       Date:  1992

Review 3.  Review of the clinical results of fast neutron therapy.

Authors:  G Schmitt; A Wambersie
Journal:  Radiother Oncol       Date:  1990-01       Impact factor: 6.280

4.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Authors:  K Dano
Journal:  Biochim Biophys Acta       Date:  1973-10-25

5.  Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.

Authors:  S M Redmond; F Joncourt; K Buser; A Ziemiecki; H J Altermatt; M Fey; G Margison; T Cerny
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

Review 6.  5-Fluorouracil by protracted venous infusion. A review of current progress.

Authors:  R M Hansen; E Quebbeman; T Anderson
Journal:  Oncology       Date:  1989       Impact factor: 2.935

7.  Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells.

Authors:  S Ahmad; R I Glazer
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

8.  Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.

Authors:  H M Coley; P R Twentyman; P Workman
Journal:  Anticancer Drug Des       Date:  1992-12

9.  Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.

Authors:  E H Oldfield; Z Ram; K W Culver; R M Blaese; H L DeVroom; W F Anderson
Journal:  Hum Gene Ther       Date:  1993-02       Impact factor: 5.695

Review 10.  Failla Memorial Lecture. Redox, radiation, and reductive bioactivation.

Authors:  G E Adams
Journal:  Radiat Res       Date:  1992-11       Impact factor: 2.841
View more
  1 in total

1.  Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells.

Authors:  Shuang-shuang Wu; Wei Xu; Shan Liu; Bo Chen; Xue-li Wang; Yan Wang; Shi-feng Liu; Jian-qing Wu
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.